Dynavax Technologies

DVAX

Market cap $1.78B

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Dynavax Technologies Corporation (NASDAQ: DVAX) related to its sale to Sanofi.

NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Please replace the release issued December 29, 2025 with the following corrected version due to multiple revisions. The updated release reads: DYNAVAX INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DYNAVAX TECHNOLOGIES CORPORATION - DVAX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale o.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under the terms of the proposed transaction, shareholders of Cidara will receive $221.50 in cash for each share of Cidara that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Sanofi is launching an all-cash tender offer for Dynavax's shares. The French pharma giant's bid comes at a sizable premium to Dynavax's recent closing price.

Biotech stock Dynavax Technologies Corp (NASDAQ:DVAX) is soaring today, last seen up 38.7% at $15.43, after reports that Sanofi (SNY) plans to acquire the company in an all-cash deal worth roughly $2.2 billion.

MILWAUKEE , Dec. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Dynavax (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Shares of Dynavax Technologies (DVAX) skyrocketed after French drugmaker Sanofi (SNY) said it would buy the biopharmaceutical firm for $2.2 billion to expand its Hepatitis B offerings and enter the shingles vaccine market.

French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult immunization market. Under the agreement, Sanofi will launch a cash tender offer of $15.50 per Dynavax share, representing a 39% premium to the company's pre-deal stock price.

Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.